

REMARKS


Claim 10 has been amended herewith. Claims 1-12 remain pending in the present application. Applicant acknowledges the Office's allowance of claims 1-9. Applicant respectfully requests reconsideration of the rejection of claims 10-12 and allowance of the application.

Claim Rejections—35 U.S.C. § 112

Claims 10-12 were rejected under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for treating the specific diseases and neurotoxicity as due to advanced glycation endproducts, does not reasonably provide—according to the Office—enablement for reversing the progression of said diseases or neurotoxicity based on any mode of action. As the Office pointed out, the specification is enabling for treating the specific diseases and neurotoxicity as due to advanced glycation endproducts. See Office Action at 2. Claim 10, as amended, is now directed to a method of slowing disease progression for treating the recited diseases and neurotoxicity by cleaving glycation endproducts or cross-linked proteins. Claims 11 and 12 depend from newly amended claim 10 and should also overcome the rejection. Accordingly, Applicant asks that the rejection be withdrawn.

In view of the above amendments and remarks, it is submitted that the claims are in condition for allowance. The Examiner is invited to telephone the undersigned to expedite allowance of this application.

Appln. No. 09/825,925
Amendment dated December 10, 2003
Reply to Office Action mailed September 10, 2003

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Michael G. Sullivan Registration No. 35,377				
SIGNATURE				DATE	December 10, 2003
Address	Rothwell, Figg, Ernst & Manbeck 1425 K Street, N.W., Suite 800				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

1954-373.amd3.wpd